U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06889623) titled 'Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer' on March 16.
Brief Summary: Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall. Immediate systemic chemotherapy post-surgery aims to eliminate microlesions promptly and minimize recurrence risk, yet its safety and efficacy require further exploration. This prospective, single-arm study delves into evaluating the efficacy and safety of immediate postoperative systemic chemotherapy...